RT Journal Article
SR Electronic
T1 MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 353
OP 359
DO 10.21873/cgp.20140
VO 16
IS 5
A1 KOVACOVA, JULIA
A1 JURACEK, JAROSLAV
A1 POPRACH, ALEXANDR
A1 KOPECKY, JINDRICH
A1 FIALA, ONDREJ
A1 SVOBODA, MAREK
A1 FABIAN, PAVEL
A1 RADOVA, LENKA
A1 BRABEC, PETR
A1 BUCHLER, TOMAS
A1 SLABY, ONDREJ
YR 2019
UL http://cgp.iiarjournals.org/content/16/5/353.abstract
AB Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. Patients and Methods: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. Results: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). Conclusion: A predictive miRNA associated with progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.